

---

# Contents

|                                          |     |
|------------------------------------------|-----|
| Foreword by <b>Bryan S. Finkle</b> ..... | vii |
| Preface .....                            | ix  |
| Contributors .....                       | xxi |

## CHAPTER 1

|                                                         |   |
|---------------------------------------------------------|---|
| Clinical Point-of-Care Testing for Drugs of Abuse ..... | 1 |
|---------------------------------------------------------|---|

**Jimmie L. Valentine**

|                                                            |   |
|------------------------------------------------------------|---|
| 1. General Considerations .....                            | 1 |
| 2. Pediatric Clinical Considerations .....                 | 2 |
| 3. Adolescent Clinical Considerations .....                | 3 |
| 4. Adult Clinical Considerations .....                     | 5 |
| 5. Physiological Considerations for Clinical Testing ..... | 7 |
| 6. Conclusions .....                                       | 8 |
| References .....                                           | 9 |

## CHAPTER 2

|                                           |    |
|-------------------------------------------|----|
| On-Site Tests for Therapeutic Drugs ..... | 11 |
|-------------------------------------------|----|

**Alan H. B. Wu**

|                                                                                  |    |
|----------------------------------------------------------------------------------|----|
| 1. Rationale for Therapeutic Monitoring and Need for On-Site Drug Testing .....  | 11 |
| 2. On-Site and Point-of-Care (POC) Drug Testing .....                            | 12 |
| 3. Direct On-Site Testing Instruments and Devices<br>for Therapeutic Drugs ..... | 13 |
| 4. Indirect On-Site Testing for Therapeutic Drugs .....                          | 15 |
| 4.1. Monitoring of Lipid Lowering Medications .....                              | 15 |
| 4.2. Monitoring of Antithrombotic Medications .....                              | 18 |
| 4.2.1. Heparin .....                                                             | 18 |
| 4.2.2. Oral Antithrombotic Therapy .....                                         | 19 |
| 4.2.3. On-Site Testing for Anticoagulant Drugs .....                             | 20 |
| 5. Conclusion .....                                                              | 22 |
| References .....                                                                 | 22 |

CHAPTER 3

On-Site Workplace Drug Testing ..... 25

**David Armbruster**

1. Background ..... 25  
2. Conducting On-Site Workplace Drug Testing ..... 30  
3. The Future of On-Site Workplace Drug Testing ..... 33  
References ..... 34

CHAPTER 4

Program Requirements, Standards, and Legal Considerations for On-Site  
Drug Testing Devices in Workplace Testing Programs ..... 37

**Theodore F. Shults and Yale H. Caplan**

1. Introduction ..... 37  
2. What Is “On-Site” Testing from a Standards Perspective? ..... 38  
3. Establishing Federal Standards for On-Site Drug Testing ..... 40  
    3.1. Drug Testing Advisory Board (DTAB) ..... 40  
        3.1.1. Collection Site ..... 42  
        3.1.2. Collector/Tester ..... 42  
        3.1.3. Collection Device/Test Device ..... 42  
        3.1.4. Specimen ..... 42  
        3.1.5. Collection Procedure ..... 43  
        3.1.6. On-Site Testing ..... 43  
        3.1.7. Laboratory Testing ..... 43  
        3.1.8. Quality Control/Quality Assurance (QC/QA) ..... 44  
        3.1.9. Reporting ..... 44  
        3.1.10. Medical Review Officer ..... 44  
    3.2. The DTAB End Game ..... 44  
4. The Legal Requirements for Confirmatory Testing  
    in Private Sector On-Site Testing ..... 44  
5. The Legal Requirements for a Medical Review Officer  
    in Private Sector On-Site Testing ..... 46  
6. New Liability Risks of Drug Testing Providers and On-Site  
    Drug Testing—Another Factor in Establishing Standards ..... 47  
7. Conclusion ..... 51  
Notes ..... 52

## CHAPTER 5

|                                                              |    |
|--------------------------------------------------------------|----|
| On-Site Testing Devices in the Criminal Justice System ..... | 55 |
|--------------------------------------------------------------|----|

**Leo J. Kadehjian and James Baer**

|                                                                           |    |
|---------------------------------------------------------------------------|----|
| 1. Drug Testing in the Criminal Justice Arena .....                       | 55 |
| 1.1. Introduction .....                                                   | 55 |
| 1.2. On-Site Testing .....                                                | 56 |
| 1.3. Use of Noninstrument Drug Testing Devices .....                      | 57 |
| 2. Legal Admissibility, Evidentiary Weight, and Due Process .....         | 60 |
| 2.1. Standards for Admissibility of Scientific Evidence .....             | 61 |
| 2.2. Cases Addressing the Use of Noninstrument Drug Testing Devices ..... | 62 |
| 2.3. Requirements for Repeat and/or Confirmation Testing .....            | 62 |
| 3. Conclusions .....                                                      | 64 |
| References .....                                                          | 64 |

## CHAPTER 6

|                                                                     |    |
|---------------------------------------------------------------------|----|
| On-Site Testing Devices and Driving-Under-the-Influence Cases ..... | 67 |
|---------------------------------------------------------------------|----|

**J. Michael Walsh**

|                                       |    |
|---------------------------------------|----|
| 1. Introduction .....                 | 67 |
| 2. On-Site Testing in DUI Cases ..... | 68 |
| 3. Summary .....                      | 75 |
| References .....                      | 75 |

## CHAPTER 7

|                                     |    |
|-------------------------------------|----|
| Analysis of Ethanol in Saliva ..... | 77 |
|-------------------------------------|----|

**Kurt M. Dubowski**

|                                                                                               |    |
|-----------------------------------------------------------------------------------------------|----|
| 1. Introduction .....                                                                         | 77 |
| 2. Saliva as a Specimen; Saliva Collection; Relationship<br>of Saliva and Blood-Alcohol ..... | 79 |
| 2.1. Saliva Collection .....                                                                  | 80 |
| 2.2. Relation of Saliva-Alcohol to Alcohol in Other Body Fluids .....                         | 80 |
| 3. Saliva-Alcohol Testing Principles and Procedures .....                                     | 82 |
| 4. Commercial Saliva-Alcohol Screening Test Devices .....                                     | 84 |
| 5. Quality Assurance .....                                                                    | 87 |
| 5.1. Testing Personnel .....                                                                  | 90 |
| 6. Interpretation and Use of Results .....                                                    | 91 |
| References .....                                                                              | 91 |

## CHAPTER 8

|                                   |    |
|-----------------------------------|----|
| Analysis of Drugs in Saliva ..... | 95 |
|-----------------------------------|----|

***Vina Spiehler, Dene Baldwin, and Christopher Hand***

|                                                  |     |
|--------------------------------------------------|-----|
| 1. Roadside or On-Site Saliva Drug Testing ..... | 95  |
| 1.1. Introduction .....                          | 95  |
| 1.2. Saliva Collection .....                     | 95  |
| 1.3. Cutoff Concentrations in Saliva .....       | 96  |
| 1.4. Amphetamines .....                          | 97  |
| 1.5. Benzodiazepines .....                       | 98  |
| 1.6. Cannabinoids .....                          | 98  |
| 1.7. Cocaine .....                               | 99  |
| 1.8. Opiates .....                               | 99  |
| 1.9. Conclusion .....                            | 99  |
| 2. Cozart RapiScan Saliva Drug Test System ..... | 100 |
| 2.1. Introduction .....                          | 100 |
| 2.2. Testing Principle .....                     | 100 |
| 2.3. Quality Control .....                       | 103 |
| 2.4. Interpretation .....                        | 103 |
| 2.5. Performance .....                           | 104 |
| 2.6. Adulteration .....                          | 107 |
| 2.7. Unique Features .....                       | 108 |
| References .....                                 | 108 |

## CHAPTER 9

|                                    |     |
|------------------------------------|-----|
| AccuSign Drugs of Abuse Test ..... | 111 |
|------------------------------------|-----|

***Johannes J. W. Ros and Marinus G. Pelders***

|                                                               |     |
|---------------------------------------------------------------|-----|
| 1. Introduction .....                                         | 111 |
| 2. The AccuSign Test Slide .....                              | 111 |
| 3. Summary of Studies .....                                   | 115 |
| 3.1. Nonpublished Pilot-Study .....                           | 115 |
| 3.2. Duo Research Report .....                                | 116 |
| 3.3. Performance of AccuSign Slide Test Near the Cutoff ..... | 117 |
| 4. Discussion .....                                           | 120 |
| 5. Conclusions .....                                          | 120 |
| 6. Product Contact Information .....                          | 121 |
| References .....                                              | 121 |

## CHAPTER 10

|                                                              |     |
|--------------------------------------------------------------|-----|
| The EZ-SCREEN and RapidTest Devices for Drugs of Abuse ..... | 123 |
|--------------------------------------------------------------|-----|

***Santo Davide Ferrara, Luciano Tedeschi, and Franca Castagna***

|                                         |     |
|-----------------------------------------|-----|
| 1. Introduction .....                   | 123 |
| 2. EZ-SCREEN .....                      | 123 |
| 2.1. Principle .....                    | 123 |
| 2.2. Materials and Reagents .....       | 125 |
| 2.3. Procedure and Interpretation ..... | 125 |
| 2.4. Performance Characteristics .....  | 125 |
| 3. RapidTest .....                      | 130 |
| 3.1. Principle .....                    | 130 |
| 3.2. Materials and Reagents .....       | 132 |
| 3.3. Procedure and Interpretation ..... | 133 |
| 3.4. Performance Characteristics .....  | 133 |
| References .....                        | 140 |

## CHAPTER 11

|                                            |     |
|--------------------------------------------|-----|
| Frontline Testing for Drugs of Abuse ..... | 143 |
|--------------------------------------------|-----|

***Serge Schneider and Robert Wennig***

|                                                      |     |
|------------------------------------------------------|-----|
| 1. Introduction .....                                | 143 |
| 2. Test Principle and Test Instructions .....        | 143 |
| 2.1. Test Principle .....                            | 143 |
| 2.2. Test Instructions .....                         | 145 |
| 3. Evaluation of the Frontline Tests .....           | 145 |
| 3.1. Crossreactivity and Cutoff Concentrations ..... | 147 |
| 3.2. Influence of Temperature .....                  | 149 |
| 3.3. Evaluation of Frontline Tests .....             | 149 |
| 4. Conclusions .....                                 | 150 |
| References .....                                     | 150 |

## CHAPTER 12

|                                                 |     |
|-------------------------------------------------|-----|
| Abuscreen ONTRAK Tests for Drugs of Abuse ..... | 153 |
|-------------------------------------------------|-----|

***Laurel J. Farrell***

|                                        |     |
|----------------------------------------|-----|
| 1. Introduction .....                  | 153 |
| 2. Principle of Abuscreen ONTRAK ..... | 153 |
| 2.1. Procedure .....                   | 154 |
| 2.2. Quality Control .....             | 159 |
| 2.3. Performance .....                 | 159 |
| References .....                       | 160 |

CHAPTER 13

The OnTrak TesTcup® System ..... 163

**Dennis J. Crouch**

1. Introduction ..... 163

2. Product Design and Theory of Drug Detection ..... 165

3. Analysis Method and Analysis Precautions ..... 166

    3.1. Method ..... 166

    3.2. Precautions ..... 167

4. Interpretation of Results ..... 168

5. Review and Discussion of the Literature ..... 170

    5.1. Study #1 ..... 170

        5.1.1. Methods ..... 170

        5.1.2. Results ..... 170

        5.1.3. Discussion ..... 172

    5.2. Study #2 ..... 172

        5.2.1. Methods ..... 172

        5.2.2. Results ..... 173

        5.2.3. Discussion ..... 173

    5.3. Study #3 ..... 173

        5.3.1. Methods ..... 173

        5.3.2. Results ..... 174

        5.3.3. Discussion ..... 174

    5.4. Study #4 ..... 175

        5.4.1. Methods ..... 175

        5.4.2. Results ..... 175

        5.4.3. Discussion ..... 176

    5.5. Study #5 ..... 176

        5.5.1. Methods ..... 176

        5.5.2. Results ..... 178

        5.5.3. Discussion ..... 178

    5.6. Study #6 ..... 179

        5.6.1. Methods ..... 179

        5.6.2. Results ..... 179

        5.6.3. Discussion ..... 179

    5.7. Study #7 ..... 180

        5.7.1. Methods ..... 180

        5.7.2. Results ..... 180

        5.7.3. Discussion ..... 180

6. Conclusions ..... 181

7. Acknowledgment ..... 182

References ..... 182

## CHAPTER 14

|                              |     |
|------------------------------|-----|
| OnTrak TesTstik Device ..... | 185 |
|------------------------------|-----|

**Salvatore J. Salamone and Jane S-C. Tsai**

|                                                      |     |
|------------------------------------------------------|-----|
| 1. Introduction .....                                | 185 |
| 2. Materials and Methods .....                       | 186 |
| 2.1. Instrumentation and Reagents .....              | 186 |
| 2.2. Precision Study Methods .....                   | 186 |
| 2.3. Clinical Evaluation and Comparative Study ..... | 187 |
| 2.4. Specificity .....                               | 187 |
| 3. The TesTstik Device .....                         | 188 |
| 4. Principle of Procedure .....                      | 189 |
| 5. Procedure .....                                   | 192 |
| 6. Performance .....                                 | 192 |
| 7. Availability .....                                | 197 |
| 8. Acknowledgments .....                             | 197 |
| References .....                                     | 197 |

## CHAPTER 15

|                                        |     |
|----------------------------------------|-----|
| Triage® Device for Drug Analysis ..... | 199 |
|----------------------------------------|-----|

**Rafael de la Torre**

|                                              |     |
|----------------------------------------------|-----|
| 1. Introduction .....                        | 199 |
| 2. Test Procedure .....                      | 200 |
| 2.1. Solution-Phase Reaction .....           | 202 |
| 2.2. Solid-Phase Reaction .....              | 202 |
| 2.3. Cutoff Definition .....                 | 203 |
| 2.4. Internal Quality Control .....          | 206 |
| 3. Clinical and Laboratory Evaluations ..... | 206 |
| References .....                             | 209 |

## CHAPTER 16

|                                              |     |
|----------------------------------------------|-----|
| Visualine II™ Drugs-of-Abuse Test Kits ..... | 213 |
|----------------------------------------------|-----|

**Scott A. Kuzdzal and James H. Nichols**

|                                          |     |
|------------------------------------------|-----|
| 1. Introduction .....                    | 213 |
| 2. Principle .....                       | 213 |
| 3. Description of Test Kits .....        | 214 |
| 4. Performance Evaluation .....          | 215 |
| 5. Management and Clinical Utility ..... | 217 |
| 6. Conclusions .....                     | 218 |

CHAPTER 17

Drugs-of-Abuse Test Devices: A Review ..... 219

**Robert E. Willette and Leo J. Kadehjian**

|                                                                                                                         |     |
|-------------------------------------------------------------------------------------------------------------------------|-----|
| 1. Introduction .....                                                                                                   | 219 |
| 1.1. Background .....                                                                                                   | 219 |
| 1.2. Study Design .....                                                                                                 | 219 |
| 1.3. Study Devices .....                                                                                                | 220 |
| 2. Results .....                                                                                                        | 221 |
| 2.1. Introduction .....                                                                                                 | 221 |
| 2.2. Analysis of Results .....                                                                                          | 221 |
| 2.3. Interpretation of the Results .....                                                                                | 222 |
| 2.4. Operator Variability .....                                                                                         | 225 |
| 2.5. Operational Characteristics .....                                                                                  | 226 |
| 3. Summary .....                                                                                                        | 227 |
| Table 1 Drug Cutoffs .....                                                                                              | 228 |
| Table 2 Amphetamine Test Results vs GC/MS—AOC Study, HHS Cutoffs .....                                                  | 228 |
| Table 3 Amphetamine Test Results vs GC/MS—AOC Study, AOC Cutoffs .....                                                  | 229 |
| Table 4 Cocaine Test Results vs GC/MS—AOC Study, HHS/AOC Cutoffs .....                                                  | 229 |
| Table 5 Opiates Test Results vs GC/MS—AOC Study, HHS Cutoffs .....                                                      | 230 |
| Table 6 Opiates Test Results vs GC/MS—AOC Study, AOC Cutoffs .....                                                      | 230 |
| Table 7 Cannabinoids Test Results vs GC/MS—AOC Study, HHA/AOC Cutoffs .....                                             | 231 |
| Table 8 Phencyclidine Test Results vs GC/MS—AOC Study, HHS/AOC Cutoffs .....                                            | 231 |
| Table 9 All Drugs Test Results vs GC/MS—AOC Study, HHS Cutoffs .....                                                    | 232 |
| Table 10 All Drugs Test Results vs GC/MS—AOC Study, AOC Cutoffs .....                                                   | 232 |
| Table 11 Amphetamines Test Results vs GC/MS—HHS Study, HHS Cutoffs .....                                                | 233 |
| Table 12 Amphetamines Test Results vs GC/MS—HHS Study, AOC Cutoffs .....                                                | 233 |
| Table 13 Cocaine Test Results vs GC/MS—HHS Study, HHS/AOC Cutoffs .....                                                 | 234 |
| Table 14 Opiates Test Results vs GC/MS—HHS Study, HHS Cutoffs .....                                                     | 234 |
| Table 15 Opiates Test Results vs GC/MS—HHS Study, AOC Cutoffs .....                                                     | 235 |
| Table 16 Cannabinoids Test Results vs GC/MS—HHS Study, HHS/AOC Cutoffs .....                                            | 235 |
| Table 17 Phencyclidine Test Results vs GC/MS—HHS Study, HHS/AOC Cutoffs .....                                           | 236 |
| Table 18 All Drugs Test Results vs GC/MS—HHS Study, HHS Cutoffs .....                                                   | 236 |
| Table 19 All Drugs Test Results vs GC/MS—HHS Study, AOC Cutoffs .....                                                   | 237 |
| Table 20 Variation in Test Results for Products Manufactured by the Same Company<br>(from HHS Study, HHS Cutoffs) ..... | 237 |
| Table 21 Product Descriptions, Operation, and Distributor Information, AOC<br>and DWP Studies .....                     |     |
| AOC Study .....                                                                                                         | 238 |
| DWP Study .....                                                                                                         | 244 |



## CHAPTER 18

|                                                  |     |
|--------------------------------------------------|-----|
| Sample Adulteration and On-Site Drug Tests ..... | 253 |
|--------------------------------------------------|-----|

**John T. Cody**

|                                     |     |
|-------------------------------------|-----|
| 1. Introduction .....               | 253 |
| 2. Dilution .....                   | 255 |
| 3. Adulterants .....                | 257 |
| 3.1. Acid .....                     | 257 |
| 3.2. Chromate .....                 | 258 |
| 3.3. Glutaraldehyde .....           | 258 |
| 3.4. Nitrite .....                  | 259 |
| 3.5. Other Adulterants .....        | 260 |
| 4. On-Site Adulteration Tests ..... | 261 |
| 5. Conclusions .....                | 262 |
| References .....                    | 262 |
| Index .....                         | 265 |



<http://www.springer.com/978-0-89603-870-7>

On-Site Drug Testing

Jenkins, A.J.; Goldberger, B. (Eds.)

2002, XXII, 270 p., Hardcover

ISBN: 978-0-89603-870-7

A product of Humana Press